UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach

Cell reports (Cambridge), 2021-12, Vol.37 (11), p.110096-110096, Article 110096

2021

Volltextzugriff (PDF)

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

Molecular & cellular oncology, 2020-03, Vol.7 (2), p.1701914-1701914

2020

Volltextzugriff (PDF)

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors

Cell communication and signaling, 2020-11, Vol.18 (1), p.179-179, Article 179

2020

Volltextzugriff (PDF)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

NPJ precision oncology, 2022-11, Vol.6 (1), p.86-86, Article 86

2022

Volltextzugriff (PDF)

Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model

Clinical cancer research, 2020-06, Vol.26 (12_Supplement_1), p.37-37

2020

Volltextzugriff (PDF)

A Biophysical Basis for a Targeted Therapy Exceptional Responder KRAS Mutation

Biophysical journal, 2020-02, Vol.118 (3), p.451a-451a

2020

Volltextzugriff (PDF)

Abstract 1102: miRNAs are key mediators of crosstalk between estrogen and progesterone regulating breast cancer invasiveness

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1102-1102

McFall, Thomas B.

2016

Volltextzugriff (PDF)

Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5509-5509

2020

Volltextzugriff (PDF)

Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen

The Journal of biological chemistry, 2018-01, Vol.293 (4), p.1163-1177

2018

Volltextzugriff (PDF)

A mechanism for the response of KRAS G13D expressing colorectal cancers to EGFR inhibitors

Molecular & cellular oncology, 2020-03, Vol.7 (2), p.1701914

2020

Volltextzugriff (PDF)

ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.754-754

2023

Volltextzugriff (PDF)

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

The oncologist (Dayton, Ohio), 2021-04, Vol.26 (4), p.e530-e536

2021

Volltextzugriff (PDF)

Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells

Molecular pharmacology, 2016-09, Vol.90 (3), p.225-237

2016

Volltextzugriff (PDF)

Abstract B43: A systems biology approach to elucidate the mechanism of EGFR inhibitor sensitivity in mutant KRAS-driven colorectal cancer

Molecular cancer research, 2020-05, Vol.18 (5_Supplement), p.B43-B43

2020

Volltextzugriff (PDF)

MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS -mutated advanced pancreatic ductal adenocarcinoma (PDAC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16260-e16260

2022

Volltextzugriff (PDF)

Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges

Oncotarget, 2015-10, Vol.6 (32), p.33146-33164

2015

Volltextzugriff (PDF)

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.859-871.e3

2024

Volltextzugriff (PDF)

Abstract 5038: Role of the short isoform of the progesterone receptor in hormone-regulated invasiveness of breast cancer cells at pre- and post-menopausal levels of estrogen and progesterone

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5038-5038

2015

Volltextzugriff (PDF)

Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer

Clinical cancer research, 2018-12, Vol.24 (24), p.6509-6522

2018

Volltextzugriff (PDF)

The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth

The Journal of biological chemistry, 2016-12, Vol.291 (50), p.25983-25998

2016

Volltextzugriff (PDF)

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241253113-17588359241253113

2024

Volltextzugriff (PDF)

Abstract 2876: The androgen receptor utilizes protein kinase docking sites to constitutively activate Elk1

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2876-2876

2016

Volltextzugriff (PDF)

Chemotherapy-free treatment targeting fusions and driver mutations in wild-type pancreatic ductal adenocarcinoma, a case series

Therapeutic advances in medical oncology, 2024-05, Vol.16

2024

Volltextzugriff (PDF)

Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor

Scientific reports, 2018-10, Vol.8 (1), p.1-15, Article 16006

2018

Volltextzugriff (PDF)

Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed

Journal of thoracic oncology, 2014-04, Vol.9 (4), p.519-526

2014

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Englisch
(121)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model

A Biophysical Basis for a Targeted Therapy Exceptional Responder KRAS Mutation

Abstract 1102: miRNAs are key mediators of crosstalk between estrogen and progesterone regulating breast cancer invasiveness

Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms

Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen

A mechanism for the response of KRAS G13D expressing colorectal cancers to EGFR inhibitors

ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells

Abstract B43: A systems biology approach to elucidate the mechanism of EGFR inhibitor sensitivity in mutant KRAS-driven colorectal cancer

MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS -mutated advanced pancreatic ductal adenocarcinoma (PDAC)

Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma

Abstract 5038: Role of the short isoform of the progesterone receptor in hormone-regulated invasiveness of breast cancer cells at pre- and post-menopausal levels of estrogen and progesterone

Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer

The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series

Abstract 2876: The androgen receptor utilizes protein kinase docking sites to constitutively activate Elk1

Chemotherapy-free treatment targeting fusions and driver mutations in wild-type pancreatic ductal adenocarcinoma, a case series

Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor

Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed

Suchergebnisse filtern